Active Ingredient History

  • Now
Dipraglurant (INN) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). As of 2014, it is in phase II clinical trials for this indication. Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia.   Wikipedia

  • SMILES: Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1
  • Mol. Mass: 265.29
  • ALogP: 2.85
  • ChEMBL Molecule:
More Chemistry
6-fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine | adx48621 | dipraglurant


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue